Cdt Dr. Jose Lopez Antongiorgi Clinic/Center - Public Health, State or Local Medicare: Not Enrolled in Medicare Practice Location: 333 Calle 25 Ne, Puerto Nuevo, PR 00920 Phone: 787-793-8989 Fax: 787-792-7355 |
News Archive
Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad' cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU's mutual recognition procedure.
As climate change increases the risk to trees from severe storms, insects, diseases, drought and fire, a Rutgers University study highlights the need for improved safety in tree-care operations.
Traumatic experiences such as assault or a road accident can give rise to nightmares, flashbacks and other mental reactions, and accessible therapy is needed to prevent exacerbation of the problems.
A new "fertility first" hypothesis published this week by a group of international experts in the American Journal of Human Biology, proposes that the global epidemic of Type 2 diabetes has its origins in the struggle, over millennia, to sustain human fertility in environments defined by famine.
People with a severe type of migraine in which one side of the body becomes weak should consider genetic testing, according to research that has found familial genes for this type of migraine in people who did not have family members experiencing the problem.
› Verified 8 days ago